Grant: Discovery Grants Program - Individual
Université de Montréal
$80,000.00
Clinical Investigation in Canine and Feline Transfusion Medicine: Novel Blood Groups and their Clinical Significance
EF 2023-24
Résumé
In veterinary medicine, the demand for blood transfusions has increase dramatically in order to support anemic and bleeding patients requiring more and more sophisticated care. Significant knowledge gaps concerning blood banking and blood compatibility in dogs and cats have been filled, but much remains to be investigated. A current concern is the threatened sustainability of blood typing for dogs and cats, and the associated loss of significant transfusion medicine knowledge, because of the lack of a reliable source of blood typing reagents. Our blood bank is a pioneer in veterinary blood transfusion with an exceptional reputation based on the quality of its blood products and of its research/publications, putting us in a unique and privileged position to address such concerns and to pursue research of novel blood groups. Our recent collaboration with the Canadian Animal Blood Bank will also facilitate large-scale clinical investigation. Briefly, dogs have a dozen blood group systems mostly known as dog erythrocyte antigens (DEA), with the most important being DEA 1. First-time transfusion is considered safe without prior cross-matching, as most dogs do not possess naturally-occurring antibodies. That said, mild immunologic incompatibilities of unknown clinical significance have been documented in some transfusion-naive dogs. As multiple blood transfusions recipients are more common, novel blood groups are likely to be identified, likewise the discovery of the Dal blood group. The rarity of Dal-negative phenotype pauses particular challenge as compatible blood is scarce. Except for DEA 1, canine blood typing relies on polyclonal reagents. Because of the limited accessibility of DEA 3, 5 and Dal typing reagents, finding compatible blood for a given patient can be arduous, and further comparative blood typing studies are limited and may become simply impossible. In opposite, the AB blood group system in cats is characterized by well-defined naturally-occurring alloantibodies. In 2007, a novel blood group named Mik was identified in cats. Since then, very little has been published on feline blood compatibility despite the fact that naturally-occurring alloantibodies outside of the AB and Mik system are known to exist. Our preliminary results indicate that 15% of cats possessed such alloantibodies, but their capacity to result in transfusion reactions remains unknown. The work outlined herein will significantly improve blood compatibility knowledge in dogs and cats. First, we will continue to investigate the clinical significance of blood groups in dogs and cats and their related alloantibodies. Second, we aim to provide long-term solution to the sustainability of veterinary blood typing by producing monoclonal typing reagent. Funding this research will improve the safety of transfusion for companion animals by generating tangible guidelines for veterinarians and will facilitate future antigenic and genotypic characterization of blood groups.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2019-04979
Name nom
Blais, Marie-Claude
Department département
Sciences Cliniques
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2019
Award amount
80000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Not available
Research subject en
Non disponible
Research subject fr
Non disponible
Application title
Clinical Investigation in Canine and Feline Transfusion Medicine: Novel Blood Groups and their Clinical Significance
Keyword
alloantibodies; blood compatibility; blood groups; blood typing; cats; crossmatch; dogs; immunogenicity; immunohematology; transfusion
Application summary
In veterinary medicine, the demand for blood transfusions has increase dramatically in order to support anemic and bleeding patients requiring more and more sophisticated care. Significant knowledge gaps concerning blood banking and blood compatibility in dogs and cats have been filled, but much remains to be investigated. A current concern is the threatened sustainability of blood typing for dogs and cats, and the associated loss of significant transfusion medicine knowledge, because of the lack of a reliable source of blood typing reagents. Our blood bank is a pioneer in veterinary blood transfusion with an exceptional reputation based on the quality of its blood products and of its research/publications, putting us in a unique and privileged position to address such concerns and to pursue research of novel blood groups. Our recent collaboration with the Canadian Animal Blood Bank will also facilitate large-scale clinical investigation. Briefly, dogs have a dozen blood group systems mostly known as dog erythrocyte antigens (DEA), with the most important being DEA 1. First-time transfusion is considered safe without prior cross-matching, as most dogs do not possess naturally-occurring antibodies. That said, mild immunologic incompatibilities of unknown clinical significance have been documented in some transfusion-naive dogs. As multiple blood transfusions recipients are more common, novel blood groups are likely to be identified, likewise the discovery of the Dal blood group. The rarity of Dal-negative phenotype pauses particular challenge as compatible blood is scarce. Except for DEA 1, canine blood typing relies on polyclonal reagents. Because of the limited accessibility of DEA 3, 5 and Dal typing reagents, finding compatible blood for a given patient can be arduous, and further comparative blood typing studies are limited and may become simply impossible. In opposite, the AB blood group system in cats is characterized by well-defined naturally-occurring alloantibodies. In 2007, a novel blood group named Mik was identified in cats. Since then, very little has been published on feline blood compatibility despite the fact that naturally-occurring alloantibodies outside of the AB and Mik system are known to exist. Our preliminary results indicate that 15% of cats possessed such alloantibodies, but their capacity to result in transfusion reactions remains unknown. The work outlined herein will significantly improve blood compatibility knowledge in dogs and cats. First, we will continue to investigate the clinical significance of blood groups in dogs and cats and their related alloantibodies. Second, we aim to provide long-term solution to the sustainability of veterinary blood typing by producing monoclonal typing reagent. Funding this research will improve the safety of transfusion for companion animals by generating tangible guidelines for veterinarians and will facilitate future antigenic and genotypic characterization of blood groups.